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Evidence based medicine is the conscientious, 
explicit, and judidous use of current best evidence 
in making decisions about the care of individual 
patients. The practice of evidence based medicine 
means integrating individual clinical expertise 
with the best available external clinical evidence 
from systematic research [1].
Evidence-based medicine is a style of practice 
and teaching which may also help plan future 
research [2]. 
There are few fields of medicine that have been subjected 
to as much scrutiny or have generated as much controversy 
as high-dose cytotoxic therapy with stem cell transplantation 
(SCT). Although transplantation has been widely accepted 
by the medical community, many ongoing clinical trials con- 
tinue to investigate accepted indications and others that are 
not firmly established. 
The American Society for Blood and Marrow Trans- 
plantation (ASBMT) initiated a project o conduct system- 
atic, evidence-based reviews of the scientific literature for 
the use of blood and marrow transplantation for specific dis- 
eases. These reviews will use evidence-based medicine 
(EBM) guidelines to define therapy as effective or ineffec- 
tive, indicate treatment that has been inadequately studied, 
and suggest areas requiring well-designed clinical trials. 
Problematic study design issues also will be identified in 
these reviews, and recommendations about the conduct of 
future trials will be made, 
In today's health care environment, EBM is sometimes 
viewed as synonymous with "cost cutting" medicine and 
may be used to refuse reimbursement forexpensive tests and 
treatments, thus limiting the clinical freedom of physicians 
and other providers. Often, however, reimbursement deci- 
sions are made not on the basis of evidence, but on a lack of 
convincing evidence. Of course, many existing "standards of 
care" were originally established on the basis of anecdotal or 
other untested evidence. They are nonetheless difficult to 
replace with new options that have not met the rigorous 
standards of modern, evidence-based medicine. 
Unfortunately, patients continue to be denied SCT 
because of its relatively high cost even when it is widely 
accepted by clinicians as the most efficacious therapy. In 
some cases, blood and marrow transplantation continues to 
be viewed as investigational or experimental. Some managed 
care organizations are reluctant to reimburse medical proce- 
dures that they perceive to be novel, investigational, or 
more expensive than conventional therapies. These reviews 
will therefore also address the issue of inadequate reim- 
bursement for transplantation i  cases where efficacy is 
widely recognized, and document i s role in treating avari- 
ety of diseases. 
SCT AS THERAPY FOR DIFFUSE LARGE CELL B-CELL 
NON-HODGKIN'S LYMPHOMA 
The first in the series of reviews, published in this issue 
of the Journal, focuses on the use of high-dose cytotoxic 
therapy and SCT for the treatment of diffuse large cell B-cell 
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non-Hodgkin's lymphonm (DLCL). The review was con- 
ducted with the guidance of an independent expert panel 
that included clinicians with expertise in the entire spectrum 
of treatment options for non-Hodgkin's lymphoma, a repre- 
sentative of a patient advocacy group, and a physician repre- 
sentative of a third-party payer organization. 
The panel reviewed nearly 350 published articles and 
recent abstract presentations on DLCL, applying criteria 
established for the project in the "ASBMT Policy Statement 
Regarding the Methodology of Evidence-Based Reviews in 
Evaluating the Role of Blood and Marrow Transplantation 
in the Treatment of Selected Diseases" [3]. The relative 
strength of treatment recommendations was graded based 
on accepted standards for evaluating the strength and qual- 
ity of the available vidence, and made with the consensus of 
the panel members. 
The systematic review of the medical iterature that was 
conducted by the expert panel documents the evidence for 
SCT in the treatment of DLCL and the relative efficacy of 
various transplantation techniques. The review also identifies 
important questions that cannot be answered with confi- 
dence due to insufficient evidence and suggests areas where 
furore research is needed. Many study design and reporting 
practices increase our awareness of inconsistencies in data 
presentation and other factors that may compromise the 
strength of the evidence, even in well-designed clinical trials. 
MAKING TREATMENT RECOMMENDATIONS 
In the DLCL review, the expert panel presents unani- 
mous consensus in its treatment recommendations and 
grades the strength of the recommendations. Of the total of 
18 recommendations, however, only 8 are definitive: 6 indi- 
cations are graded as "effective treatment," 2 as "not an 
effective treatment" and 10 as "inadequately evaluated treat- 
ment and recommended for comparative study." 
LIMITATIONS OF CURRENT RESEARCH AND FUTURE 
RESEARCH NEEDS 
An important goal of the ASBMT evidence-based 
review process is to identify areas where additional research 
is most needed. Based on the evidence available to them, the 
DLCL expert panel identified 5 major disease-related ques- 
tions and 5 treatment-related questions that remain to be 
answered. It is our hope that the review will help advance 
knowledge in the field of SCT by providing an objective 
assessment of areas where investigators might best focus 
their future research efforts. 
An especially important lesson learned from the review 
process is that it is imperative to adhere to certain standards 
in conducting studies related to SCT. Among the criteria 
established at the outset of the review by the expert panel 
was that studies would be included only if the study popula- 
tion comprised a minimum of 70% DLCL patients, unless 
the results were stratified by histology subtype. Many stud- 
ies, including well-designed randomized trials and registry 
reports addressing issues such as comparisons between 
autologous and allogeneic transplantation and between 
PBSCT and BMT, were excluded because of this and other 
methodologic ssues. It also became apparent that there is a 
wide variance in the way DLCL is defined. Some clinicians, 
for example, include anaplastic large cell lymphoma in the 
definition of DLCL, whereas others do not. 
RECOMMENDATIONS TO STRENGTHEN THE EVIDENCE 
We strongly support he recommendation f the expert 
panel that all clinical studies specify the lymphoma classifi- 
cation schema and percentage of histologic subtype. With- 
out this information, it is difficult to judge whether a study's 
results are applicable to a specific histology; or to compare 
the conclusions of various tudies. 
The availability of the International Prognostic Index 
[4] was not among the inclusion criteria for the DLCL 
review because most of the phase II I  trials were accruing 
patients or had been analyzed before the IPI project was 
published. Nonetheless, ignificant differences in prognoses 
and outcomes based on IPI scores have been identified, and 
the applicability of study results may be problematic if the 
study does not state patients' IPI risk categories. It is rec- 
ommended that patients be identified by IPI score in all 
future publications. 
Any evidence-based review of the medical literature must 
be viewed as a work in progress, and revisited at regular inter- 
vals to assess new evidence. It is also important to remember 
that, while such reviews are valuable aids to physicians and 
other decision makers, they have limitations. High-quality 
evidence does not exist in many areas of clinical practice and 
may never be available due to the practical limitations of con- 
ducting large-scale randomized trials, ethical issues, and other 
factors. Support of government and the insurance industry 
for well-designed prospective trials necessary to develop qual- 
ity evidence isan essential component of this process. 
Despite their drawbacks, systematic reviews of available 
evidence play an increasingly important role in health care, 
improve confidence in treatment and reimbursement deci- 
sions, and help assure that good research findings are 
applied more quickly to clinical practice. 
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